|
WO2018223103A1
|
|
Compositions and methods for tumor vaccination and immunotherapy involving her antigens
|
|
AU2018272085A1
|
|
Combination immunotherapies comprising IL-15 superagonists
|
|
AU2017297610A1
|
|
Compositions and methods for alphavirus vaccination
|
|
EP3484509A1
|
|
Compositions and methods for flavivirus vaccination
|
|
CN110114086A
|
|
For using the composition and method of prostate cancer related antigen tumor vaccination
|
|
KR20190033483A
|
|
Compositions and methods for the treatment of human papillomavirus (HPV) -related diseases
|
|
AU2017273878A1
|
|
Compositions and methods for tumor vaccination and immunotherapy involving HER2/neu
|
|
EP3463440A1
|
|
Neoepitope vaccine compositions and methods of use thereof
|
|
KR20180101529A
|
|
Methods and compositions for influenza vaccination
|
|
KR20180101540A
|
|
Methods and compositions for T cell immunotherapy
|
|
WO2016172249A1
|
|
Methods and compositions for combination immunotherapy
|
|
CA2974237A1
|
|
Methods and compositions for combination immunotherapy
|
|
CA2973109A1
|
|
Methods and compositions for ebola virus vaccination
|
|
WO2014031178A1
|
|
Replication defective adenovirus vector in vaccination
|
|
EP3061462A1
|
|
Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
|
